Aurora kinase B (AURKB) is a mitotic serine/threonine protein kinase that belongs to the
aurora kinase family along with aurora kinase A (AURKA) and aurora kinase C (AURKC) …

Current microtubule-targeting agents (MTAs) remain amongst the most important antimitotic
drugs used against a broad range of malignancies. By perturbing spindle assembly, MTAs …

Glioblastoma (GBM) is the most common type of malignant tumor of the central nervous
system. The prognosis of patients with GBM is very poor, with a survival time of~ 15 months …

The identification of clinically-relevant biomarkers is of upmost importance for the
management of cancer, from diagnosis to treatment choices. We performed a pan-cancer …

Hepatocellular carcinoma (HCC) is highly resistant to chemotherapy. Previously, we have
shown that Aurora-A mRNA is upregulated in HCC cells or tissues and silencing of Aurora-A …

Glioblastoma multiforme is the most frequent primary malignancy of the central nervous
system. Despite remarkable progress towards an understanding of tumor biology, there is no …

Compounds that affect enzymatic function of kinases are valuable for the understanding of
the complex biochemical processes in cells. Aurora kinases (AURKs) play a key role in the …

Biological networks display high robustness against random failures but are vulnerable to
targeted attacks on central nodes. Thus, network topology analysis represents a powerful …

High‐grade gliomas are aggressive, deadly primary brain tumors. Median survival of
patients with glioblastoma (GBM, WHO grade 4) is 14 months and< 10% of patients survive …

Previously, transcriptomic profiling studies have shown distinct molecular subtypes of
glioblastomas. It has also been suggested that the recurrence of glioblastomas could be …